Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Naloxone Talk Sheds Light On Switch Research Future

This article was originally published in The Tan Sheet

Executive Summary

FDA’s 2012 workshop on potential nonprescription use of naloxone for opioid overdoses underscored the potential usefulness of human factors research in the evolving landscape for switch. Largely considered a sub-category of self-selection studies, human factors research could gain importance as FDA moves into considering novel switches.

You may also be interested in...



OTC Switch Interest Cooled By Study Costs To Update Safety Data

Firms often are hesitant to prepare Rx-to-OTC switch applications because safety and efficacy data for their products are over a decade old, notes health care consultant Laura Mahecha.

OTC Switch Interest Cooled By Study Costs To Update Safety Data

Firms often are hesitant to prepare Rx-to-OTC switch applications because safety and efficacy data for their products are over a decade old, notes health care consultant Laura Mahecha.

Allowing States To Ban Abortion Services Increases Calls For Making Birth Control Available OTC

Supreme Court’s six conservative justices say Constitution doesn’t guarantee a woman’s right to abortion services nor prohibit states from regulating or banning the services. Dissenting liberal members decry decision as erasing women’s constitutional rights.

Topics

Latest News
UsernamePublicRestriction

Register

PS106161

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel